[Mono- or combination therapy with myocardial and coronary active drugs in ischemic heart disease].
The medicamentous treatment of the ischaemic heart disease with nitrates, beta-receptor blockers and calcium antagonists takes into account the in the ideal case evident pathomechanism and the essential principles of the effect of these groups of pharmaca. Apart from the influence on way of life and environmental factors at first the monotherapy is tried. As a rule, in individually possible full use of the dose a large part of the patients can sufficiently be improved. As to "conventional therapy", however, from the first the concerning the therapeutic mechanism favorable combination beta-receptor blocker and nitrates is understood. The increasing interest in calcium antagonists aprt from the increased application of these pharmaca in monotherapy led to the question of the combination with beta-receptor blockers and nitrates. Taking into consideration the different spectres of action of the calcium antagonists particularly in unstable angina pectoris, especially under haemodynamically controlled conditions a combination of three remedies is to be discussed. With regard to this there are no sufficient clinical experiences. At present there are no sufficient evidences for the superiority of this combination therapy.
Urbaszek
W
W
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D009566:Nitrates / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D009566:Nitrates
Mono- oder Kombinationstherapie myokard- bzw. koronarwirksamer Pharmaka bei ischämischer Herzkrankheit.